Dr. Niu earned his medical degree and completed residency training in general surgery at China Medical University before relocating to the United States to complete a doctorate degree in molecular pharmacology and subsequently a postdoctoral fellowship in pharmacology at the University of Illinois-Chicago. Dr. Niu completed a second residency in internal medicine at Cook County Hospital in Chicago and fellowship training in hematology/oncology at Baylor College of Medicine in Houston, Texas.

Dr. Niu is a triple board-certified in internal medicine, hematology, and medical oncology. He joined Banner MD Anderson Cancer Center (BMDACC) in 2016 and has been focusing on clinical practice and research in lung, head & neck cancers. He currently serves as co-director of lung cancer program and lead medical oncologist for head and neck cancer program.

Dr. Niu has over 25 years of experience in both basic and clinical research. His passion is early drug development in oncology. Dr. Niu is well published and was actively involved in the development of several new oncology drugs including Palbociclib, Cemiplimab, Mobocertinib, leading to FDA approval. Most recently Dr. Niu led an international phase I study on Vibostolimab, a TIGIT inhibitor, which is currently being studied in multiple phase II and phase III studies. He is the principal investigator or co-principal investigator for 12 ongoing clinical trials at BMDACC.